Meeting
2017 ASCO Annual Meeting
A phase I study of sequential ipilimumab in the definitive treatment of node positive cervical cancer: GOG 9929.
Authors
Jyoti Mayadev
University of California, Davis, Sacramento, CA
Jyoti Mayadev , William E. Brady , Yvonne Gail Lin , Diane M Da Silva , Heather A. Lankes , Paula M. Fracasso , Sharad A. Ghamande , Kathleen N. Moore , Huyen Q. Pham , Kelly Jeanes Wilkinson , Vanessa Amy Kennedy , Carol Aghajanian , Wui-Jin Koh , Bradley J. Monk , Russell J. Schilder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
NCT01711515
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5526)
DOI
10.1200/JCO.2017.35.15_suppl.5526
Abstract #
5526
Poster Bd #
348
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Combination of nivolumab with chemoradiotherapy for locally advanced cervical cancer: NiCOL phase I trial.
First Author: Manuel Rodrigues
Poster
2018 ASCO Annual Meeting
A phase I dose-finding study of metformin in combination with concurrent cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Shuchi Gulati
Poster
2017 ASCO Annual Meeting
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer.
First Author: Linda R. Duska
Poster
2014 ASCO Annual Meeting
Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC).
First Author: Maria Catherine Pietanza